Drug intelligence / Profile preview

DSP-0509 + pembrolizumab

Development stage: Unknown
Lead developer: Sumitomo Pharma America
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intratumoral, Intravenous

Overview

DSP-0509 (guretolimod) is a small molecule agonist of Toll-like receptor 7 (TLR7), designed to stimulate innate immune responses within the tumor microenvironment. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor activity. The combination of DSP-0509 and pembrolizumab aims to synergistically activate both innate and adaptive immunity, potentially converting immunologically "cold" tumors into "hot" tumors that are more responsive to immunotherapy. This combination has been investigated in phase 1/2 clinical trials for patients with advanced solid tumors, with Sumitomo Dainippon Pharma Oncology as the developer[1][4][6][8].

Other names: none

Targets

PDCD1 (Programmed cell death protein 1 receptor)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on DSP-0509 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DSP-0509 + pembrolizumab.

Explore the full profile